Shapiro on Transplantation

 
 
  • From A2 to B: Shortening the Wait for a Kidney   Dr. Ron Shapiro looks at a study in which blood type A2 kidneys were transplanted into recipients with blood types O and B in an effort to shorten the waiting time for transplantation.
  • Does Glucose Intolerance Preclude Kidney Donation?   Dr. Ron Shapiro discusses a study examining whether eligibility criteria for living kidney donors could be expanded to include persons with either glucose intolerance or oral-agent-dependent diabetes.
  • Telltale Signs of Cardiovascular Risk in Renal Transplant Patients   Dr. Ron Shapiro reviews a study that found that inflammatory cytokine genotypes can indicate cardiovascular risk in kidney transplant recipients.
  • Trends in Solid Organ Transplantation   The latest data, as reviewed by Dr. Ron Shapiro, show that waiting lists for most solid organ transplantations have stabilized or decreased over time.
  • Minimally Invasive Nephrectomy Is Largely Safe   Dr. Ron Shapiro reports on a single center’s 10-year experience in performing 1200 laparoscopic donor nephrectomies.
  • When a Kidney Fails After Transplantation   Conventional wisdom suggests foregoing transplant nephrectomy if kidney failure occurs more than 1 year after transplantation. Dr. Ron Shapiro looks at a study that contradicts this strategy.
  • Single-Donor Islet Transplant Success Improved by Insulin-Heparin Infusions   Islet transplantation can mean insulin independence for diabetes patients, but many require multiple islet infusions. Dr. Ron Shapiro discusses an approach that improves single-donor success.
  • Bortezomib and Antibody-Mediated Renal Allograft Rejection   Dr. Ron Shapiro looks at 2 small studies that, taken together, may indicate the role of bortezomib in antibody-mediated renal allograft rejection.
  • Belatacept May Change Kidney Transplantation Medicine   A novel agent, belatacept, may preserve renal function and improve long-term outcomes better than calcineurin inhibitors in kidney transplantation. Dr. Ron Shapiro discusses 2 pivotal trials.
  • Hypothermic Machine Preservation in Human Liver Transplantation   Hypothermic machine preservation has been used for liver preservation only in animal models. Dr. Ron Shapiro reviews the first trial to use this strategy in human liver transplantation.
  • Alemtuzumab Shows Promise in Cardiac Transplantation   Alemtuzumab induction primarily has been used in renal transplantation, but Dr. Ron Shapiro reviews a study in which this agent greatly reduces incidence of rejection in cardiac transplantation.
  • Prevention of BK Virus in Kidney Transplantation Confirmed by 5-Year Follow-up Study   A landmark study in the prevention of BK viruria or viremia in kidney transplant recipients is confirmed by a 5-year follow-up study, discussed here by Dr. Ron Shapiro.
  • High-Dose Everolimus Improves Graft Survival in Renal Transplantation   High-dose everolimus and low-dose cyclosporine may provide benefit in renal transplantation. Dr. Ron Shapiro comments on a randomized study in which this combination resulted in excellent outcomes.
  • CVD: A Major Complication of Pediatric Renal Transplantation   CVD is a significant complication in pediatric renal transplant recipients. Dr. Ron Shapiro discusses disturbing results of a study in which mortality among these patients was exceedingly high.
  • Mumps: Not an Innocent Bystander in Solid Organ Transplantation   In this video blog, Dr. Ron Shapiro discusses a case report of mumps reinfection leading to allograft failure in a stable renal transplant patient.
  • Coronary Stents in Pediatric Heart Transplant Recipients   Could coronary stents serve as palliative therapy for pediatric heart transplant patients with CAD? Dr. Ron Shapiro discusses a study that suggests this as a viable strategy.
  • Sirolimus for Refractory GVHD   Dr. Ron Shapiro discusses the implications of a Parisian study that found sirolimus effective for the treatment of refractory graft-vs-host disease in bone marrow transplant recipients.
  • Is Hepatitis C Infection a Contraindication to Heart Transplantation?   In kidney transplantation, hepatitis C seropositivity is not a barrier to transplantation. Is it a barrier to heart transplantation? Dr. Ron Shapiro discusses a study that looks at this issue.
  • Mycophenolate Mofetil or Azathioprine: Which Is Better?   Although MMF has replaced AZA in most centers, there is a paucity of data on the relative merits of these agents. In this videoblog, Dr. Ron Shapiro comments on a study confirming MMF as superior.
  • Islet Grafting in a Bioengineered Space   In this video blog, Dr. Ron Shapiro looks at a study that uses an intramuscular site bioengineered to better support islet survival and that permits PET imaging of the transplanted beta-cell mass.